Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study

Lookup NU author(s): Dr Stuart McCracken, Professor Damian Greene

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2021, The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.Introduction: Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). Methods: Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason


Publication metadata

Author(s): Shah TT, Reddy D, Peters M, Ball D, Kim NH, Gomez EG, Miah S, Evans DE, Guillaumier S, van Rossum PSN, Van Son MJ, Hosking-Jervis F, Dudderidge T, Hindley R, Emara A, McCracken S, Greene D, Nigam R, McCartan N, Valerio M, Minhas S, Afzal N, Lewi H, Ogden C, Persad R, Virdi J, Moore CM, Arya M, Emberton M, Ahmed HU, Winkler M

Publication type: Article

Publication status: Published

Journal: Prostate Cancer and Prostatic Diseases

Year: 2021

Volume: 24

Pages: 567–574

Print publication date: 01/06/2021

Online publication date: 28/01/2021

Acceptance date: 11/12/2020

ISSN (print): 1365-7852

ISSN (electronic): 1476-5608

Publisher: Springer Nature

URL: https://doi.org/10.1038/s41391-020-00315-y

DOI: 10.1038/s41391-020-00315-y


Altmetrics

Altmetrics provided by Altmetric


Share